MB Act for bio Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2023 |
|---|
| 24,021 |
| - |
| 3,870 |
| 3,767 |
| - |
| 94.14 |
| 15.68 |
| 2,553 |
| 712 |
| 0 |
| 3,265 |
| 0.11 |
| 0.28 |
| - |
| - |
| 16.11 |
| 3,870 |
| 2024 |
|---|
| 24,688 |
| - |
| 4,664 |
| 4,370 |
| - |
| 94.90 |
| 17.70 |
| 6,922 |
| 344 |
| 0 |
| 7,266 |
| 0.28 |
| 0.05 |
| - |
| - |
| 18.89 |
| 4,664 |
| 2025 |
|---|
| 30,306 |
| - |
| 1,263 |
| 1,165 |
| - |
| 95.67 |
| 3.84 |
| 8,087 |
| 11,946 |
| 16,373 |
| 3,660 |
| 0.11 |
| 1.48 |
| - |
| - |
| 5.21 |
| 1,578 |
| 2025 |
|---|
| 30,306 |
| - |
| 1,263 |
| 1,165 |
| - |
| 95.67 |
| 3.84 |
| 8,087 |
| 11,946 |
| 16,373 |
| 3,660 |
| 0.11 |
| 1.48 |
| - |
| - |
| 5.21 |
| 1,578 |
Turnover (€)
2025
Turnover (€)
30,306 €23 % *
Sales per employee (€)
-Profit before tax (€)
1,263 €-73 % *
Net Profit (€)
1,165 €-73 % *
Profit per employee (€)
-Total profitability (%)
95.67 %0.81 % *
Net profitability (%)
3.84 %-78.31 % *
Equity (€)
8,087 €17 % *
Amounts Payable And Liabilities (€)
11,946 €3,373 % *
Non-current Assets (€)
16,373 €- *
CurrentAssets (€)
3,660 €-50 % *
Working capital requirement
0.11 -60.71 % *
Debt-to-equity ratio
1.48 2,860.00 % *
EBITDA margin (%)
-EBITDA (€)
-EBIT margin (%)
5.21 %-72.42 % *
EBIT (€)
1,578 €-66 % *
